Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA58623
Max Phase: Preclinical
Molecular Formula: C42H44O11
Molecular Weight: 724.80
Molecule Type: Small molecule
Associated Items:
ID: ALA58623
Max Phase: Preclinical
Molecular Formula: C42H44O11
Molecular Weight: 724.80
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)/C=C/c4ccc5ccccc5c4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Standard InChI: InChI=1S/C42H44O11/c1-23-29(51-32(45)18-16-25-15-17-26-11-9-10-14-28(26)19-25)21-42(49)37(52-38(48)27-12-7-6-8-13-27)35-40(5,36(47)34(46)33(23)39(42,3)4)30(44)20-31-41(35,22-50-31)53-24(2)43/h6-19,29-31,34-35,37,44,46,49H,20-22H2,1-5H3/b18-16+/t29-,30-,31+,34+,35-,37-,40+,41-,42+/m0/s1
Standard InChI Key: MYSWFMUVRHEUJM-LUZZEONASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 724.80 | Molecular Weight (Monoisotopic): 724.2884 | AlogP: 4.50 | #Rotatable Bonds: 6 |
Polar Surface Area: 165.89 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 11 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.64 | CX Basic pKa: | CX LogP: 4.62 | CX LogD: 4.62 |
Aromatic Rings: 3 | Heavy Atoms: 53 | QED Weighted: 0.14 | Np Likeness Score: 2.25 |
1. Ojima I, Bounaud PY, Takeuchi C, Pera P, Bernacki RJ.. (1998) New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells., 8 (2): [PMID:9871652] [10.1016/s0960-894x(97)10218-9] |
2. Huang Q, Kirikae F, Kirikae T, Pepe A, Amin A, Respicio L, Slayden RA, Tonge PJ, Ojima I.. (2006) Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents., 49 (2): [PMID:16420032] [10.1021/jm050920y] |
3. Hurley KA, Santos TM, Nepomuceno GM, Huynh V, Shaw JT, Weibel DB.. (2016) Targeting the Bacterial Division Protein FtsZ., 59 (15): [PMID:26756351] [10.1021/acs.jmedchem.5b01098] |
Source(1):